News Breaks |
|
|
| March 7, 2013 |
| 06:21 EDT |  | CADX, BMY, BAX | Cadence announces supply agreement with Laboratorios Grifols
Cadence Pharmaceuticals (CADX) announced a new supply agreement with Laboratorios Grifols, S.A. for the development, manufacture and supply of commercial quantities of OFIRMEV injection in flexible plastic bags. Previously, Cadence announced the extension of its supply arrangement for OFIRMEV in glass vials with Lawrence Laboratories, a member of the Bristol Myers Squibb (BMY) group of companies, through December 31, 2018. Additionally, the company has terminated its development and supply agreement for OFIRMEV in glass vials with Baxter Healthcare Corporation (BAX). |
|
|
News For CADX;BMY;BAX From The Last 14 Days Check below for free stories on CADX;BMY;BAX the last two weeks. |
|
|
| May 23, 2013 |
| 06:02 EDT |  | BMY | Bristol-Myers implied volatility at upper end of index mean range
|
|
| 05:47 EDT | | BMY | Stocks with implied volatility movement; SKS BMY
Stocks with implied volatility movement; Saks (SKS), Bristol-Myers (BMY) according to IVolatility. |
|
| May 22, 2013 |
| 16:00 EDT | | BMY | Options Update; May 22, 2013
 Subscribe for More Information |
|
| 10:33 EDT | | BMY | Bristol-Myers jumps after Citi ups rating on cancer potential
Subscribe for More Information |
|
| 10:16 EDT |  | BMY | Bristol-Myers spikes higher following upgrade, levels to watch
Subscribe for More Information |
|
| 10:00 EDT |  | BMY | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 06:05 EDT | | BMY | Bristol-Myers upgraded to Buy from Neutral at Citigroup
Subscribe for More Information |
|
| May 21, 2013 |
| 09:09 EDT | | BAX | Baxter granted authorization by European Commission for use of HyQvia
Baxter International (BAX) and Halozyme Therapeutics (HALO) announced that the European Commission has granted Baxter marketing authorization in all European Union Member States for the use of HyQvia as replacement therapy for adult patients with primary and secondary immunodeficiencies. Baxter will introduce HyQvia in select countries during 2013 and plans to expand the launch to other EU countries in 2014. |
|
| 07:34 EDT |  | BMY | UBS to host a conference
Subscribe for More Information |
|
| 07:24 EDT | | BMY | Global Health Care to host a conference
Subscribe for More Information |
| |
| May 20, 2013 |
| 10:03 EDT | | BMY | Shire advances after report renews takeover speculation
Subscribe for More Information |
|
| 06:30 EDT |  | BMY | Leerink estimates Shire takeout value at least $110 per share
Leerink says a takeover price for Shire (SHPG) would need to be at least $110 per share in order to get the company's board to consider a sale. The firm notes a Daily Mail report last night said Bristol-Myers (BMY) has engaged advisors to study an acquisition of Shire and that Shire's CEO has contacted bankers to consider anti-takeover measures. Leerink believes a Bristol-Myers takeover of Shire would make sense and keeps an Outperform rating on Shire. |
|
| 06:25 EDT |  | BMY | Shire may return cash to thwart takeover, Daily Mail reports
Subscribe for More Information |
|
| May 17, 2013 |
| 13:21 EDT | | BMY | Options with increasing implied volatility: CPRT BMY GDI HNZ
Subscribe for More Information |
|
| May 16, 2013 |
| 16:32 EDT | | BMY | Bristol-Myers announces intention to voluntarily delist preferred stock
Subscribe for More Information |
|
| 13:20 EDT | | BMY | Follow-up: Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Bristol-Myers citing the company's multi-billion dollar immuno-oncology prospects. The firm says there were additional responses reported in the press briefing with combination nivolumab and Yervoy. Leerink has a $51 price target for shares. |
|
| 13:14 EDT | | BMY | Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information |
|
| 08:55 EDT | | BMY | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| 08:38 EDT | | BMY | Bristol-Myers shares likely to give back recent gains, says Leerink
Leerink expects shares of Bristol-Myers to give back recent gains after ASCO published abstracts last night. The firm found the abstracts as in-line with, but not above, its expectations for nivolumab alone or immuno-oncology combination therapy and keeps a Market Perform rating on Bristol-Myers. |
|
| 05:52 EDT | | BMY | Stocks with implied volatility movement; BMY SLV
Subscribe for More Information |
| |
|
|
|
|
